<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557661</url>
  </required_header>
  <id_info>
    <org_study_id>NIL-CDNP-CT002</org_study_id>
    <nct_id>NCT00557661</nct_id>
  </id_info>
  <brief_title>Safety Study of CD-NP in Heart Failure</brief_title>
  <official_title>A Multi-Center, Ascending Dose Trial to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CD-NP Infusions in Patients With Congestive Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nile Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nile Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label study designed to determine the safety, tolerability and pharmacodynamics of
      CD-NP infusions in heart failure patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of CD-NP infusions in patients with heart failure</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of CD-NP infusions on urinary flow rate, urinary sodium and potassium excretion</measure>
    <time_frame>24 hrs</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Congestive Heart Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD-NP</intervention_name>
    <description>24 hr intravenous infusion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female â‰¥18 years of age diagnosed with NYHA class III or IV heart failure in
             the last six months

          -  Female patients must be post-menopausal or surgically sterile

          -  Diagnosed heart failure with left ventricular ejection fraction &lt;40% obtained within
             the prior 6 months with at least one symptoms or signs of volume overload

        Key Exclusion Criteria:

          -  Women who are pregnant, breast-feeding or of child-bearing potential

          -  Clinically unstable patients

          -  Major surgical procedures within 30 days of entry

          -  Febrile temp &gt; 100 degrees F)

          -  Symptomatic carotid disease, critical carotid stenosis, or stroke within 3 months
             prior to study entry

          -  Currently on IV vasoactive support (e.g., heart transplant candidate)

          -  History of unexplained syncope within the past 3 months

          -  History of organ transplantation

          -  Comorbidities such as clinically significant cardiac valvular stenosis, aortic
             valvular disease, restrictive cardiomyopathy, hypertrophic obstructive cardiomyopathy,
             constrictive pericarditis, primary pulmonary hypertension, infiltrative disease,
             uncorrected congenital heart disease, acute coronary syndrome, restrictive heart
             failure, or any other condition which, in the opinion of the Investigator, would
             prevent a patient's participation in the study.

          -  Participation in a clinical trial of any investigational therapy or device within 30
             days prior to randomization.

          -  Treatment with nesiritide within 14 days prior to dosing.

          -  Inability to effectively communicate with study personnel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Goldsmith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hennepin County Medical Center, Minneapolis</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2007</study_first_submitted>
  <study_first_submitted_qc>November 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <last_update_submitted>March 23, 2009</last_update_submitted>
  <last_update_submitted_qc>March 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2009</last_update_posted>
  <keyword>Heart failure</keyword>
  <keyword>CD-NP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

